Candel Therapeutics Inc (CADL) received rating reaffirmations from four firms from November 13, 2026 through November 16, 2026. Four bullish, zero neutral, zero bearish. No firm changed its rating.
| Firm | Rating | Tier |
|---|---|---|
| Canaccord Genuity | Buy | bullish |
| Citigroup | Buy | bullish |
| HC Wainwright & Co. | Buy | bullish |
| Stifel | Buy | bullish |
The past 90 days include six active firms, with six rating the stock bullish. 10 analysts set consensus price targets as of November 10, 2026, with a mean of $23.33, a median of $24.48 and a range of $15.15 to $30.45.
For Q4 FY2026, analysts expect EPS of -$0.38 and revenue of $0. The next earnings report is scheduled for March 10, 2027.
